The Europe Sickle Cell Disease Treatment Market would witness market growth of 27.4% CAGR during the forecast period (2023-2030).
The sickled cells that give the illness its name can cause severe damage to organs like the heart and kidneys, as well as pain throughout the body. Mild to moderate anemia is frequently present in people with sickle cell disease. However, they may get severe anemia, which is considered fatal.
Red blood cells are constantly in short supply because sickle cells expire prematurely. They likewise become caught and obstruct the flow of blood as they pass through tiny blood arteries. This may result in discomfort as well as more severe health issues like an infection, acute chest syndrome, and stroke. SCD comes in a variety of forms. A person's particular form of SCD is determined by the genes they acquired from their parents. Genes that encode defective hemoglobin are inherited by people with SCD.
Throughout the region, millions of people suffer with sickle cell disease. Hemoglobin gene mutations can result in genotypic and phenotypic variations of sickle cell anemia. Throughout the forecast period, the market expansion is anticipated to be driven by the condition's high frequency and the ailment's rising severity.
According to the National Institute for Health and Care Excellence (NICE), there are currently 12,500–15,000 people in England who have sickle cell disease, and according to data from NHS Digital, there were 24,573 hospital admissions in England in 2020–2021 where sickle cell disorders were the primary diagnosis. The average age of these hospitalizations was 29 years, and 35% were emergency admissions. One-fourth of those who were admitted were under the age of 18. Hence, with rise in the occurrence of disease, the market is estimated to grow.
The Germany market dominated the Europe Sickle Cell Disease Treatment Market by Country in 2022; thereby, achieving a market value of $482.7 Million by 2030. The UK market is exhibiting a CAGR of 26.3% during (2023 - 2030). Additionally, The France market would experience a CAGR of 28.3% during (2023 - 2030).
Based on Treatment, the market is segmented into Blood Transfusion, Pharmacotherapy, and Bone Marrow Transplant. Based on End-Use, the market is segmented into Hospitals, Specialty Clinics and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Worldwide Sickle Cell Disease Treatment Market is Projected to reach USD 7.3 Billion by 2030, at a CAGR of 27.9%
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Novartis AG, Pfizer Inc., bluebird bio, Inc., CSL Limited, Emmaus Life Sciences, Inc., Bristol Myers Squibb Company, CRISPR Therapeutics AG, Agios Pharmaceuticals, Inc. (LES LABORATOIRES SERVIER SAS), Novo Nordisk A/S and Medunik USA (Duchesnay Inc.).
Scope of the Study
Market Segments Covered in the Report:
By Treatment
- Blood Transfusion
- Pharmacotherapy
- Bone Marrow Transplant
By End-Use
- Hospitals
- Specialty Clinics
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Novartis AG
- Pfizer Inc.
- bluebird bio, Inc.
- CSL Limited
- Emmaus Life Sciences, Inc.
- Bristol Myers Squibb Company
- CRISPR Therapeutics AG
- Agios Pharmaceuticals, Inc. (LES LABORATOIRES SERVIER SAS)
- Novo Nordisk A/S
- Medunik USA (Duchesnay Inc.)
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Sickle Cell Disease Treatment Market, by Treatment
1.4.2 Europe Sickle Cell Disease Treatment Market, by End-Use
1.4.3 Europe Sickle Cell Disease Treatment Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
Chapter 4. Competition Analysis - Global
4.1 KBV Cardinal Matrix
4.2 Recent Industry Wide Strategic Developments
4.2.1 Partnerships, Collaborations and Agreements
4.2.2 Product Launches and Product Expansions
4.2.3 Acquisition and Mergers
4.2.4 Trials and Approvals
4.3 Top Winning Strategies
4.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
4.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements: 2019, Feb – 2022, Jun) Leading Players
4.4 Porter Five Forces Analysis
Chapter 5. Europe Sickle Cell Disease Treatment Market by Treatment
5.1 Europe Blood Transfusion Market by Country
5.2 Europe Pharmacotherapy Market by Country
5.3 Europe Bone Marrow Transplant Market by Country
Chapter 6. Europe Sickle Cell Disease Treatment Market by End-use
6.1 Europe Hospitals Market by Country
6.2 Europe Specialty Clinics Market by Country
6.3 Europe Others Market by Country
Chapter 7. Europe Sickle Cell Disease Treatment Market by Country
7.1 Germany Sickle Cell Disease Treatment Market
7.1.1 Germany Sickle Cell Disease Treatment Market by Treatment
7.1.2 Germany Sickle Cell Disease Treatment Market by End-use
7.2 UK Sickle Cell Disease Treatment Market
7.2.1 UK Sickle Cell Disease Treatment Market by Treatment
7.2.2 UK Sickle Cell Disease Treatment Market by End-use
7.3 France Sickle Cell Disease Treatment Market
7.3.1 France Sickle Cell Disease Treatment Market by Treatment
7.3.2 France Sickle Cell Disease Treatment Market by End-use
7.4 Russia Sickle Cell Disease Treatment Market
7.4.1 Russia Sickle Cell Disease Treatment Market by Treatment
7.4.2 Russia Sickle Cell Disease Treatment Market by End-use
7.5 Spain Sickle Cell Disease Treatment Market
7.5.1 Spain Sickle Cell Disease Treatment Market by Treatment
7.5.2 Spain Sickle Cell Disease Treatment Market by End-use
7.6 Italy Sickle Cell Disease Treatment Market
7.6.1 Italy Sickle Cell Disease Treatment Market by Treatment
7.6.2 Italy Sickle Cell Disease Treatment Market by End-use
7.7 Rest of Europe Sickle Cell Disease Treatment Market
7.7.1 Rest of Europe Sickle Cell Disease Treatment Market by Treatment
7.7.2 Rest of Europe Sickle Cell Disease Treatment Market by End-use
Chapter 8. Company Profiles
8.1 bluebird bio, Inc.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Research & Development Expenses
8.1.4 Recent strategies and developments:
8.1.4.1 Partnerships, Collaborations, and Agreements:
8.1.5 SWOT Analysis
8.2 CRISPR Therapeutics AG
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Research & Development Expenses
8.2.4 Recent strategies and developments:
8.2.4.1 Partnerships, Collaborations, and Agreements:
8.2.5 SWOT Analysis
8.3 Agios Pharmaceuticals, Inc. (Les Laboratoires Servier SAS)
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Research & Development Expenses
8.3.4 Recent strategies and developments:
8.3.4.1 Trials and Approvals:
8.3.5 SWOT Analysis
8.4 Medunik USA (Duchesnay Inc.)
8.4.1 Company Overview
8.4.2 Recent strategies and developments:
8.4.2.1 Trials and Approvals:
8.4.3 SWOT Analysis
8.5 CSL Limited
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 SWOT Analysis
8.6 Novo Nordisk A/S
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental & Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.6.5.2 Acquisition and Mergers:
8.6.6 SWOT Analysis
8.7 Novartis AG
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expense
8.7.5 Recent strategies and developments:
8.7.5.1 Partnerships, Collaborations, and Agreements:
8.7.5.2 Trials and Approvals:
8.7.6 SWOT Analysis
8.8 Pfizer, Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional & Segmental Analysis
8.8.4 Research & Development Expense
8.8.5 Recent strategies and developments:
8.8.5.1 Acquisition and Mergers:
8.8.6 SWOT Analysis
8.9 Bristol Myers Squibb Company
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expenses
8.9.5 SWOT Analysis
8.10. Emmaus Life Sciences, Inc.
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Research & Development Expenses
8.10.4 Recent strategies and developments:
8.10.4.1 Partnerships, Collaborations, and Agreements:
8.10.4.2 Product Launches and Product Expansions:
8.10.4.3 Trials and Approvals:
8.10.5 SWOT Analysis
TABLE 1 Europe Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 2 Europe Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Sickle Cell Disease Treatment Market
TABLE 4 Product Launches And Product Expansions– Sickle Cell Disease Treatment Market
TABLE 5 Acquisition and Mergers– Sickle Cell Disease Treatment Market
TABLE 6 Trials and Approvals- SICKLE Cell Disease Treatment Market
TABLE 7 Europe Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 8 Europe Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 9 Europe Blood Transfusion Market by Country, 2019 - 2022, USD Million
TABLE 10 Europe Blood Transfusion Market by Country, 2023 - 2030, USD Million
TABLE 11 Europe Pharmacotherapy Market by Country, 2019 - 2022, USD Million
TABLE 12 Europe Pharmacotherapy Market by Country, 2023 - 2030, USD Million
TABLE 13 Europe Bone Marrow Transplant Market by Country, 2019 - 2022, USD Million
TABLE 14 Europe Bone Marrow Transplant Market by Country, 2023 - 2030, USD Million
TABLE 15 Europe Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 16 Europe Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 17 Europe Hospitals Market by Country, 2019 - 2022, USD Million
TABLE 18 Europe Hospitals Market by Country, 2023 - 2030, USD Million
TABLE 19 Europe Specialty Clinics Market by Country, 2019 - 2022, USD Million
TABLE 20 Europe Specialty Clinics Market by Country, 2023 - 2030, USD Million
TABLE 21 Europe Others Market by Country, 2019 - 2022, USD Million
TABLE 22 Europe Others Market by Country, 2023 - 2030, USD Million
TABLE 23 Europe Sickle Cell Disease Treatment Market by Country, 2019 - 2022, USD Million
TABLE 24 Europe Sickle Cell Disease Treatment Market by Country, 2023 - 2030, USD Million
TABLE 25 Germany Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 26 Germany Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 27 Germany Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 28 Germany Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 29 Germany Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 30 Germany Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 31 UK Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 32 UK Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 33 UK Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 34 UK Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 35 UK Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 36 UK Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 37 France Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 38 France Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 39 France Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 40 France Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 41 France Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 42 France Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 43 Russia Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 44 Russia Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 45 Russia Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 46 Russia Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 47 Russia Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 48 Russia Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 49 Spain Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 50 Spain Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 51 Spain Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 52 Spain Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 53 Spain Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 54 Spain Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 55 Italy Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 56 Italy Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 57 Italy Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 58 Italy Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 59 Italy Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 60 Italy Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 61 Rest of Europe Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 62 Rest of Europe Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 63 Rest of Europe Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 64 Rest of Europe Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 65 Rest of Europe Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 66 Rest of Europe Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 67 Key Information – bluebird bio, Inc.
TABLE 68 Key Information – CRISPR Therapeutics AG
TABLE 69 Key Information – Agios Pharmaceuticals, Inc.
TABLE 70 Key Information – Medunik USA
TABLE 71 Key Information – CSL Limited
TABLE 72 Key Information – Novo Nordisk A/S
TABLE 73 Key Information – Novartis AG
TABLE 74 Key Information – Pfizer, Inc.
TABLE 75 Key Information – Bristol Myers Squibb Company
TABLE 76 Key Information – Emmaus Life Sciences, INC.
List of Figures
FIG 1 Methodology for the research
FIG 2 Europe Sickle Cell Disease Treatment Market, 2019 - 2030, USD Million
FIG 3 Key Factors Impacting Sickle Cell Disease Treatment Market
FIG 4 KBV Cardinal Matrix
FIG 5 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 6 Key Strategic Move: Partnerships, Collaborations & Agreements: 2019, Feb – 2022, Jun) Leading Players
FIG 7 Porter’s Five Forces Analysis – Sickle Cell Disease Treatment Market
FIG 8 Europe Sickle Cell Disease Treatment Market share by Treatment, 2022
FIG 9 Europe Sickle Cell Disease Treatment Market share by Treatment, 2030
FIG 10 Europe Sickle Cell Disease Treatment Market by Treatment, 2019 - 2030, USD Million
FIG 11 Europe Sickle Cell Disease Treatment Market share by End-use, 2022
FIG 12 Europe Sickle Cell Disease Treatment Market share by End-use, 2030
FIG 13 Europe Sickle Cell Disease Treatment Market by End-use, 2019 - 2030, USD Million
FIG 14 Europe Sickle Cell Disease Treatment Market share by Country, 2022
FIG 15 Europe Sickle Cell Disease Treatment Market share by Country, 2030
FIG 16 Europe Sickle Cell Disease Treatment Market by Country, 2019 - 2030, USD Million
FIG 17 SWOT Analysis: bluebird bio, Inc.
FIG 18 SWOT Analysis: CRISPR Therapeutics AG
FIG 19 SWOT Analysis: Agios Pharmaceuticals, Inc.
FIG 20 SWOT Analysis: Medunik USA
FIG 21 SWOT Analysis: CSL Limited
FIG 22 SWOT Analysis: Novo Nordisk A/S
FIG 23 Recent strategies and developments: Novartis AG
FIG 24 SWOT Analysis: Novartis AG
FIG 25 SWOT Analysis: Pfizer, Inc.
FIG 26 SWOT Analysis: Bristol Myers Squibb Company
FIG 27 Recent strategies and developments: Emmaus Life Sciences, Inc.
FIG 28 SWOT Analysis: Emmaus Life Sciences, Inc.